Kestra Private Wealth Services LLC Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kestra Private Wealth Services LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,923 shares of the company’s stock after acquiring an additional 139 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in IDEXX Laboratories were worth $795,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Angeles Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company’s stock valued at $545,000 after buying an additional 25 shares during the last quarter. Cranbrook Wealth Management LLC lifted its stake in IDEXX Laboratories by 7.0% during the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock valued at $158,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC boosted its holdings in shares of IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock valued at $632,000 after acquiring an additional 26 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of IDEXX Laboratories by 4.0% in the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company’s stock worth $356,000 after acquiring an additional 27 shares during the period. Finally, Concurrent Investment Advisors LLC raised its holdings in shares of IDEXX Laboratories by 4.7% during the third quarter. Concurrent Investment Advisors LLC now owns 630 shares of the company’s stock valued at $318,000 after purchasing an additional 28 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 over the last 90 days. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Down 3.3 %

IDXX stock opened at $444.53 on Friday. The business’s 50-day moving average price is $430.77 and its 200-day moving average price is $453.31. The stock has a market cap of $36.40 billion, a P/E ratio of 41.66, a PEG ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research analyst reports. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.